COX-2 gene rs689466 polymorphism is associated with increased risk of colorectal cancer among Caucasians: a meta-analysis

Yong-Chen Zhang
The second Hospital of Nanjing, Nanjing University of Chinese Medicine

Hui Zhao
Affiliated Hospital of Jiangnan University

Chen Chen (chenchen20112020@126.com)
Huaian First People's Hospital

Mohammad Amzad Ali
Pandit Madan Mohan Malaviya government hospital Malviya Nagar

Keywords: COX-2, colorectal cancer, susceptibility, polymorphism

DOI: https://doi.org/10.21203/rs.3.rs-17753/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Several studies have reported the Cyclooxygenase 2 (COX-2) rs689466 polymorphism as a susceptibility locus of colorectal cancer (CRC), but their findings are inconsistent. Thus, this meta-analysis was performed to more accurately identify the effects of this polymorphism on CRC risk.

Methods: Potential case-control studies on EMBASE, Google of Scholar, Web of Science, Cochrane Library, and PubMed were searched. The strength of association was quantified by pooled odds ratio and 95% confidence interval. Totally 16 articles involving 8,998 cases and 11,917 controls were included. Results: None of the five tested genetic models revealed an association between rs689466 polymorphism and CRC risk. Stratified analysis by ethnicity uncovered a positive association between this polymorphism and higher CRC risk in Caucasians, but not in Asians. In addition, we found high expression of COX-2 was associated with better overall survival for all CRC patients. Conclusion: To sum up, the COX-2 rs689466 polymorphism may be related with susceptibility to CRC in Caucasians. This finding should be verified by larger-size studies with different ethnic groups.

Introduction

Colorectal cancer (CRC), the second largest cause of cancer-induced death in the world [1], was estimated to cause 135,430 new cases and 50,260 deaths in the US in 2017 [2]. However, the cause of CRC is unknown yet. Risk of CRC is significantly associated with diet, cigarette smoking, drinking and other factors [3, 4]. The development of CRC also involves genetic factors [5].

Cyclooxygenases (COXs), including two isoforms of COX-1 and COX-2 identified so far, are critical in transforming arachidonic acid to the precursor of prostaglandins – prostaglandin H2 [6]. COX-2 overexpression in CRC tissues was associated with worse overall survival of CRC [7]. Paeonol, a COX-2 inhibitor, constrains prostaglandin E2 (PGE2) generation and COX-2 expression, thereby preventing human CRC cells from tumors [8]. COX-2 downregulation considerably eliminates the development, motion and invasion of colon cancer [9]. These observations suggest COX-2 is pivotal in CRC development.

COX-2 containing 10 exon counts is located in the chromosome 1q31.1. Rs689466 polymorphism is in the promoter zone of COX-2 gene. The association between rs689466 polymorphism and CRC risk has been explored extensively [10-25]. However, the findings of these studies were inconclusive and inconsistent, which may be attributed to the small sample sizes, clinical heterogeneity and ethnic differences. To solve the inconsistence among these studies, we designed this meta-analysis to clarify the potential association between COX-2 gene rs689466 polymorphism and CRC risk.

Materials And Methods

Literature search and inclusion criteria

Two reviewers systematically and independently searched EMBASE, Google of Scholar, Web of Science, Cochrane Library, and PubMed to find potential studies without any restriction. The key words included “polymorphism”, “single nucleotide polymorphism” or “SNP”, “colorectal cancer”, “colorectal tumor” or “CRC”, and “Cyclooxygenase-2” or “COX-2”. References of identified studies were manually screened to search any omitted article.

The inclusion criteria were (1) case-control studies; (2) enough data for computation of pooled odd ratio (OR) with 95% confidence interval (CI); (3) evaluation of association between COX-2 rs689466 polymorphism and CRC risk; (4) target at humans.

Prognosis analysis

Oncolnc (http://www.oncolnc.org/) website was used to evaluate prognostic value of the mRNA expression (high vs. low expression, separated by 50%) of COX-2 gene. We analyzed the overall survival (OS) of CRC patients by calculating Log rank p-value and hazard ratio (HR) with 95% confidence intervals.

Expression analysis

We also performed the expression quantitative trait loci (eQTL) analysis using GTEx portal web site (http://www.gtexportal.org/home/) to predict potential associations between the SNPs and gene expression levels.

Data isolation and quality assessment

Based on the inclusion criteria, two reviewers independently extracted the data of interest, including ethnicity, sample sizes (cases, controls), cancer type, name of first author, publication year, and country of origin. If data were unavailable in an article, we contacted the authors for relevant data. If more than one ethnicity were involved in one article, we collected genotype data separately.
The quality of each included study was assessed using the Newcastle-Ottawa Scale (NOS) [26]. Generally, a score from 5 to 9 stars indicates high methodological quality while a score from 0 to 4 mean slow quality. Disagreements between the two reviewers were solved by discussion or consultancy with a third reviewer.

**Statistical analysis**

Statistical analyses were carried out using Stata 11.0 (StataCorp, College Station, USA). Stratified analyses of ethnicity, source of control (SOC), Hardy–Weinberg equilibrium (HWE) and genotyping methods were also conducted. Regarding potential heterogeneity among studies, we defined significant heterogeneity at the levels $P < 0.10$ and $I^2 > 50\%$. A random-effect model was used in case of significant heterogeneity; otherwise a fixed-effect model was used [27]. The effect on heterogeneity test and the stability of results were evaluated via sensitivity analysis by eliminating one study each time.

HWE in the controls was examined via Pearson's $\chi^2$ test. The positive findings were evaluated by calculating false-positive report probability (FPRP). An FPRP threshold of 0.2 and a prior probability of 0.1 were set to detect an OR for a correlation with the tested genotype. FPRP < 0.2 implied a possible relationship. Publication bias was tested by visually inspecting the symmetry of Begg's funnel plot and assessing Egger's test [28]. The Power and Sample Size Program software was used to calculate power and sample size. The following parameters are used: $\alpha$, the type I error probability for a two-sided test; $P_0$, the probability of exposure in controls; $N$ is the number of case patients; $m$, the ratio of control to experimental subjects; $\Psi$, odd ratio of exposure in cases relative to controls. Statistical significance was set at $P < 0.05$.

**Results**

**Characteristics of included articles**

The initial search returned 161 articles. Then 43 duplicated articles were excluded, and 75 articles were omitted after title and abstract examination. Of the remaining 43 articles, full-text review denied 27 articles. Finally, 16 studies with 8,998 cases and 11,917 controls were included [10-25]. The process of article selection is illustrated in Figure 1. The characteristics of the included studies are listed in Table 1. Two ethnicities were involved, including Caucasians (12 studies) [12-14, 16-21, 23-25] and Asians (4 studies) [10, 11, 15, 22]. Two studies failed to conform to HWE [15, 22]. The NOS scores range from 5 to 7 stars, suggesting the included studies are all of high quality.

**Quantitative analysis**

We evaluated the association between COX-2 gene expression and CRC prognosis using Oncolnc website. Our data showed that high expression of COX-2 was associated with better OS for all CRC patients (HR, 0.66; 95%CI, 0.45 – 0.98; $p = 0.0357$, Figure 2). We speculated that COX-2 may be a tumor suppressor gene.

We also conducted a meta-analysis between an important single nucleotide polymorphism (SNP) of COX-2 gene and CRC risk, and found the COX-2 rs689466 polymorphism is not associated with CRC risk (G vs. A: OR =1.06 (95%CI: 0.94 – 1.19), $p = 0.363$, Figure 3; GG + AG vs. AA: 1.08 (0.95 – 1.24), $p = 0.237$; GG vs. AG + AA: 1.06 (0.84 – 1.32), $p = 0.627$; GG vs. AA: 1.10 (0.84 – 1.44), $p = 0.478$; GA vs. AA: 1.07 (0.95 – 1.21), $p = 0.453$, Table 2). Nevertheless, an association between CRC risk and COX-2 rs689466 polymorphism was obtained in Caucasians (G vs. A: OR = 1.15 (95%CI: 1.02 – 1.29), $p < 0.05$, Figure 4), but not in Asians. Stratified analysis by HWE and genotyping methods revealed no association either in HWE-positive studies (GG + AG vs. AA OR, 1.12 (95%CI: 0.99 – 1.27), $p = 0.068$, Table 3) or HWE-negative studies. Stratified analysis of SOC showed rs689466 polymorphism was associated with increased risk for hospital-based population. In addition, we found that rs689466 polymorphism was associated with the expression of COX-2 gene according to the result on GTEx portal data (Supplementary Figure 1).

**Sensitivity analysis and publication bias**

Sensitivity analysis shows no single study largely influenced the pooled data, indicating our results are statistically robust. Neither Begg's funnel plot (GG + AG vs. AA, Figure 5) nor Egger's test finds any publication bias.

**Power analysis and FPRP analyses**

The power analysis revealed that this study had a power of 89.8% to detect the effect of rs689466 polymorphism on CRC susceptibility among Caucasians, assuming an OR of 1.15. Table 4 presented the FPRP values at different $p$ level. The FPRPs for positive associations were much larger, indicating some possible bias due to limited sample size. Larger-sized studies are needed to confirm these findings.

**Discussion**
This meta-analysis showed no relationship between COX-2 rs689466 polymorphism and CRC risk in the whole populations. However, stratified analyses of ethnicity and SOC indicated that rs689466 polymorphism was associated with higher CRC risk among Caucasians and hospital-based populations.

CRC is the third leading cancer, but its occurrence and death rates vary largely among different areas in the world [29]. The lifetime risk of CRC development is ~ 5% in many regions [1]. About 45% of diagnosed CRC patients die, regardless of therapy [1]. The COX-2 mRNA levels are over-expressed in almost 80% of CRC patients [30]. COX-2 inhibitors are promising candidates for chemoprevention of CRC in clinic [31, 32]. The use of COX-2 inhibitor may help to improve the outcomes of stage I CRC patients [33]. Abovementioned data suggested that COX-2 may participate in the development of CRC. Rs689466 polymorphism is a pivotal SNP of COX-2 gene. The G allele rs689466 polymorphism was reported to transcriptionally activate COX-2 in colon cancer cells [34]. Thus, we assumed this SNP may be associated with the risk of CRC. Recently, a host of studies investigated the relationship between COX-2 rs689466 polymorphism and CRC risk [10-25]. A case-control study from Netherlands observed no association between this SNP and CRC risk [16], which was consistent with the findings of some Caucasian studies. However, positive association was also obtained among other Caucasians [12, 18, 19]. Of the four studies from China, two studies found no association between COX-2 rs689466 polymorphism and CRC risk [11, 22], while the other two studies demonstrated a correlation between this polymorphism and lower CRC risk [10, 15]. To solve these inconsistencies, Wang et al. conducted a meta-analysis involving 5 studies (1,854 cases and 2,950 controls), and concluded COX-2 rs689466 polymorphism was not associated with CRC susceptibility [35]. Similarly, another meta-analysis also suggested COX-2 rs689466 polymorphism was not associated with CRC risk in the overall population, or in the stratified analyses of ethnicity, cancer location, SOC or HWE [36]. We think the previous two meta-analyses have some limitations. Firstly, Wang et al [35] omitted three studies meeting the inclusion criteria [10, 15, 16] and did not conduct stratified analyses of SOC or HWE. Secondly, Peng et al. omitted a study [11] and did not analyze the origin of heterogeneity. Therefore, their findings should be interpreted with caution. To date, several emerging studies have been reported since these meta-analyses. Consequently, it is necessary to conduct a comprehensive meta-analysis that included these new studies to determine whether the COX-2 rs689466 polymorphism was associated with CRC risk.

Herein, we included 16 studies with larger sample sizes (8,998 cases and 11,917 controls) in this meta-analysis. Although our results suggested COX-2 rs689466 polymorphism was not associated with a higher CRC risk in the overall population, subgroup analysis of ethnicity showed that COX-2 rs689466 polymorphism was associated with increased CRC risk in Caucasians, but not in Asians, suggesting different racial inheritance for Caucasians and Asians. The ethnic difference may be explained by the different allele frequency of this polymorphism. Asians have higher A allele frequency than Caucasians (European) (0.494 vs. 0.194). Another reason may be the differences among ethnic groups in sample sizes. In this meta-analysis, the sample sizes of Caucasians and Asians were different. Furthermore, varied living environments and diets may be important factors. In addition, clinical heterogeneity may also contribute to contradictory findings. As reported, G allele of rs689466 polymorphism could transcriptionally activate COX-2 [34]. We supposed this SNP may regulate COX-2 gene transcription and protein translation, thereby involving in the development of CRC. Additionally, we found high expression of COX-2 was associated with better OS for CRC patients. To be frankly, the development of CRC is attributed to multiple genes, genetic background and environmental factors. Further studies that considered environmental and genetic factors were urgently needed.

This meta-analysis has several limitations. Firstly, subgroup analyses of age, sex, smoking, drinking status or tumor size were not conducted due to data shortage. Secondly, estimates of confounding factors were unadjusted, which might affect the final results. Thirdly, possible gene-gene and gene-environment interactions were ignored because of data insufficiency. Fourthly, only Asians and Caucasians were included and the findings may be inapplicable to other racial groups. Fifthly, we did not explore the association between rs689466 polymorphism and COX-2 protein. Lastly, only four Asian studies were included in this meta-analysis.

In conclusion, this meta-analysis confirms an association between COX-2 gene rs689466 polymorphism and increased CRC risk among Caucasians. Nevertheless, this finding should be validated by further studies in other ethnicities.

**Declarations**

**Compliance with ethical standards**

**Conflict of interest**

The authors declare that there are no competing interests associated with the manuscript.

**Ethical approval**

Not required since previously published data were analyzed.

**Informed consent**

No patient was recruited to the present study.
Author Contributions

Conceptualization, Chen Chen and Mohammad Amzad Ali; Methodology, Yong-Chen Zhang; Validation, Yong-Chen Zhang and Hui Zhao; Formal Analysis, Yong-Chen Zhang and Hui Zhao; Investigation, Yong-Chen Zhang and Hui Zhao; Resources, Chen Chen and Yong-Chen Zhang; Data Curation, Hui Zhao and Mohammad Amzad Ali; Writing-Original Draft Preparation, Chen Chen and Mohammad Amzad Ali; Writing-Review and Editing, Yong-Chen Zhang, Chen Chen and Mohammad Amzad Ali.

Abbreviations

COX-2: Cyclooxygenase-2; CRC: Colorectal cancer; COXs: Cyclooxygenases; PGE2: prostaglandin E2; OR: odd ratio; CI: confidence interval; OS: overall survival; NOS: Newcastle-Ottawa; SOC: Scale; source of control; HWE: Hardy–Weinberg equilibrium.

Acknowledgements

None.

Availability of Data and Materials

The relevant data could be available when the corresponding author was contacted.

Funding

None

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893-917.
2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30.
3. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002; 94(13):972-80.
4. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001; 131(11 Suppl):3109S-20S.
5. Valle L. Genetic predisposition to colorectal cancer: where we stand and future perspectives. World J Gastroenterol. 2014; 20(29):9828-49.
6. DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta. 1991; 1083(2):121-34.
7. Peng L, Zhou Y, Wang Y, Mou H, Zhao Q. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature. PLoS One. 2013; 8(3):e58891.
8. Li M, Tan SY, Wang XF. Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE(2) synthesis and COX-2 expression. Oncol Rep. 2014; 32(6):2845-53.
9. Che XH, Chen CL, Ye XL, Weng GB, Guo XZ, Yu WY, et al. Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro. Oncol Rep. 2016; 35(3):1680-8.
10. Zhang Y, Liu C, Peng H, Zhang J, Cai X, Zhang Q. Promoter polymorphisms of cyclooxygenase-2 gene and the susceptibility to colorectal cancer. World Chinese Journal of Digestology. 2012; 12(17):1579-84.
11. Ruan Y, Sun J, Wu F, Jiang S. Relationship between COX-2 gene polymorphism and the risk of colorectal cancer. International Journal of Digestive Disease. 2013; 11(04):260-3+72.
12. Vogel LK, Saebø M, Hoyer H, Kopp TI, Vogel U, Godiksen S, et al. Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis. PLoS One. 2014; 9(8):e105254.
13. Tomitao MTP, Nahas SC, Kubrusly MS, Furuya TK, Diniz MA, Marie SKN, et al. Cyclooxygenase-2 gene polymorphisms and susceptibility to colorectal cancer in a Brazilian population. J Gastrointest Oncol. 2017; 8(4):629-35.
14. Thompson CL, Plummer SJ, Merkulova A, Cheng I, Tucker TC, Casey G, et al. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol. 2009; 15(18):2240-4.
15. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet-12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis. 2007; 28(6):1197-201.
16. Siezen CL, Tijhuis MJ, Kram NR, van Soest EM, de Jong DJ, Fodde R, et al. Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics. 2006; 16(1):43-50.

17. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer. 2006; 119(2):297-303.

18. Shomaf M, Yousef AL, Ababna N, Bobali Y. Cyclooxygenase-2 (COX2) gene polymorphisms and the risk of sporadic colorectal cancer and polyps among Jordanian population. Turk J Gastroenterol. 2015; 26(2):154-8.

19. Pereira C, Queiros S, Galagher A, Sousa H, Pimentel-Nunes P, Brandao C, et al. Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLC02A1) and their involvement in colorectal cancer development. PLoS One. 2014; 9(4):e92000.

20. Pereira C, Pimentel-Nunes P, Brandao C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol. 2010; 22(5):607-13.

21. Makar KW, Poole EM, Resler AJ, Seufert B, Curtin K, Kleinstein SE, et al. COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations. Cancer Causes Control. 2013; 24(12):2059-75.

22. Li S, Zhao X, Wu Z, Li Y, Zhu L, Cui B, et al. Polymorphisms in arachidonic acid metabolism-related genes and the risk and prognosis of colorectal cancer. Fam Cancer. 2013; 12(4):755-65.

23. Hoff JH, te Morsche RH, Roelofs HM, Nagengast FM, Peters WH. COX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer risk. World J Gastroenterol. 2009; 15(36):4561-5.

24. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009; 9:407.

25. Andersen V, Holst R, Kopp Ti, Tjonneland A, Vogel U. Interactions between diet, lifestyle and IL10, IL1B, and PTGS2/COX-2 gene polymorphisms in relation to risk of colorectal cancer in a prospective Danish case-cohort study. PLoS One. 2013; 8(10):e78366.

26. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5.

27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58.

28. Wassen L, Jertborn M. Influence of exogenous reproductive hormones on specific antibody production in genital secretions after vaginal vaccination with recombinant cholera toxin B subunit in humans. Clin Vaccine Immunol. 2006; 13(2):202-7.

29. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64(10):1637-49.

30. Roelofs HM, Te Morsche RH, van Heumen BW, Nagengast FM, Peters WH. Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterol. 2014; 14:1.

31. Kraus S, Naumov I, Arber N. COX-2 active agents in the chemoprevention of colorectal cancer. Recent Results Cancer Res. 2013; 191:95-103.

32. Kim SH, Margalit O, Katoh H, Wang D, Wu H, Xia D, et al. CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models. Invest New Drugs. 2014; 32(6):1105-12.

33. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015; 107(1):345.

34. Pereira C, Sousa H, Silva J, Brandao C, Elgueta-Karstegl C, Farrell PJ, et al. The -1195G allele increases the transcriptional activity of cyclooxygenase-2 gene (COX-2) in colon cancer cell lines. Mol Carcinog. 2014; 53 Suppl 1:E92-5.

35. Wang J, Guo X, Zhang J, Song J, Ji M, Yu S, et al. Cyclooxygenase-2 polymorphisms and susceptibility to colorectal cancer: a meta-analysis. Yonsei Med J. 2013; 54(6):1353-61.

36. Peng Q, Yang S, Lao X, Tang W, Chen Z, Lai H, et al. Meta-analysis of the association between COX-2 polymorphisms and risk of colorectal cancer based on case-control studies. PLoS One. 2014; 9(4):e94790.

Tables

Table 1 Characteristic of studies on the association between COX-2 rs689466 polymorphism and colorectal cancer.
| Author and Year | Country   | Ethnicity | SOC   | Genotyping method | Case  | Control | p values* | HWE | NOS |
|----------------|-----------|-----------|-------|-------------------|-------|---------|-----------|-----|-----|
| Siezen2005     | Netherlands | Caucasian | PB    | pyrosequencing    | 218   | 131  22 | 255  122   | 16  >0.05 | 0.77 | 7   |
| Siezen2006     | Netherlands | Caucasian | PB    | pyrosequencing    | 410   | 191  29 | 665  354   | 61  >0.05 | 0.13 | 6   |
| Tan2007        | China      | Asian     | PB    | PCR-RFLR          | 320   | 502  178| 308  692   | 300 >0.05 | 0.02 | 6   |
| Andersen2009   | Denmark    | Caucasian | PB    | Taqman QPCR       | 230   | 116  13 | 482  258   | 25  0.88 | 0.177 | 7   |
| Hoff2009       | Netherlands | Caucasian | PB    | PCR-RFLR          | 213   | 101  12 | 232  124   | 13  0.99 | 0.471 | 8   |
| Thomopson2009  | USA        | Caucasian | PB    | Taqman            | 275   | 138  9  | 297  168   | 15  0.99 | 0.131 | 7   |
| Pereira2010    | Portugal   | Caucasian | HB    | PCR-RFLR          | 70    | 43   4  | 177  73    | 6   0.078 | 0.634 | 7   |
| Zhang2012      | China      | Asian     | HB    | PCR-RFLR          | 77    | 216  50 | 62   184    | 94  <0.05 | 0.09 | 6   |
| Ruan2013       | China      | Asian     | HB    | PCR-RFLR          | 34    | 67   29 | 39   53     | 28  0.847 | 0.232 | 6   |
| Andersen2013   | Denmark    | Caucasian | PB    | PCR               | 587   | 313  47 | 1126 560  | 61  0.09  | 0.397 | 7   |
| Li2013         | China      | Asian     | HB    | PCR-RFLR          | 116   | 248  87 | 179  366   | 114 0.34  | 0.002 | 6   |
| Makar2013      | USA        | Caucasian | PB    | Illumina          | 1529  | 742  90 | 2156 1005 | 130 0.05  | 0.343 | 8   |
| Pereira2014    | Portugal   | Caucasian | PB    | Taqman            | 143   | 85   15 | 323  133   | 16  0.076 | 0.614 | 7   |
| Vogel2014      | Norway     | Caucasian | PB    | KASPTM            | 626   | 284  23 | 209  114   | 11  0.262 | 0.337 | 8   |
| Shomaf2015     | Jordan     | Caucasian | HB    | PCR-RFLR          | 68    | 61   6  | 87   27    | 1   0.13  | 0.483 | 7   |
| Tomitao2017    | Brazil     | Caucasian | HB    | Taqman            | 146   | 72   12 | 135  55    | 6   0.17  | 0.89  | 7   |

*p values for the association between COX-2 gene rs689466 polymorphism and colorectal cancer risk from original article. HB, hospital-based controls; PB, population-based controls; SOC, source of controls; PCR-RFLR, polymerase chain reaction-restriction fragment length polymorphism; KASPTM, competitive allele-specific polymerase chain reaction; QPCR, quantitative real-time polymerase chain reaction; HWE, Hardy–Weinberg equilibrium; NOS, Newcastle–Ottawa Scale.

**Table 2** The association between COX-2 rs689466 polymorphism and colorectal cancer risk under different genetic models.

| Genetic models                  | OR(95%CI)  | p(OR) | Model | I²(%) | p(H) |
|---------------------------------|------------|-------|-------|-------|------|
| Allele model (G vs. A)          | 1.06(0.94,1.19) | 0.363 | Random | 81.7  | <0.001 |
| Dominant model (GG+AG vs. AA)   | 1.08(0.95,1.24) | 0.237 | Random | 75.9  | <0.001 |
| Recessive model (GG vs. AG+AA)  | 1.06(0.84,1.32) | 0.627 | Random | 66.8  | <0.001 |
| Homozygous model (GG vs. AA)    | 1.10(0.84,1.44) | 0.478 | Random | 73.5  | <0.001 |
| Heterozygous model (AG vs. AA)  | 1.07(0.95,1.21) | 0.257 | Random | 66.5  | <0.001 |

OR, Odds ratio; CI, confidence interval; p (H), p for heterogeneity.

**Table 3** Meta-analysis of the association between COX-2 rs689466 polymorphism and colorectal cancer risk.
| Variables   | No. | Allele model | OR(95%CI) | $p_{het}$ | Dominant model | OR(95%CI) | $p_{het}$ | Recessive model | OR(95%CI) | $p_{het}$ | Homozygous model | OR(95%CI) | $p_{het}$ | Heterozygous model | OR(95%CI) | $p_{het}$ |
|-------------|-----|--------------|-----------|-----------|----------------|-----------|-----------|----------------|-----------|-----------|------------------|-----------|-----------|-------------------|-----------|-----------|
| Ethnicity   |     |              |           |           |                |           |           |                |           |           |                  |           |           |                   |           |           |
| Caucasian   | 12  | 1.15(1.02,1.29) | <0.001   | 1.14(1.00,1.30) | <0.001 | 1.23(0.99,1.53) | 0.138 | 1.28(1.00,1.65) | 0.042 | 1.11(0.98,1.25) | 0.005 |
| Asian       | 4   | 0.82(0.67,1.01) | 0.004    | 0.89(0.65,1.22) | 0.006 | 0.76(0.52,1.11) | 0.002 | 0.75(0.46,1.21) | 0.001 | 0.94(0.70,1.26) | 0.024 |
| SOC         |     |              |           |           |                |           |           |                |           |           |                  |           |           |                   |           |           |
| PB          | 10  | 1.03(0.91,1.18) | <0.001   | 1.01(0.88,1.16) | <0.001 | 1.10(0.86,1.41) | 0.001 | 1.10(0.80,1.52) | <0.001 | 1.00(0.88,1.12) | 0.002 |
| HB          | 6   | 1.14(0.84,1.54) | <0.001   | 1.32(0.95,1.83) | 0.002 | 1.03(0.60,1.76) | 0.001 | 1.17(0.65,2.10) | 0.002 | 1.33(1.00,1.78) | 0.022 |
| HWE         |     |              |           |           |                |           |           |                |           |           |                  |           |           |                   |           |           |
| Positive    | 14  | 1.09(0.96,1.23) | <0.001   | 1.12(0.99,1.27) | <0.001 | 1.11(0.85,1.46) | <0.001 | 1.17(0.89,1.55) | <0.001 | 1.11(0.99,1.24) | 0.008 |
| Negative    | 2   | 0.90(0.64,1.26) | 0.001    | 0.83(0.52,1.35) | 0.003 | 0.90(0.57,1.40) | 0.016 | 0.81(0.40,1.64) | 0.001 | 0.84(0.57,1.25) | 0.021 |
| Genotyping  |     |              |           |           |                |           |           |                |           |           |                  |           |           |                   |           |           |
| Pyrosequencing | 2   | 1.04(0.72,1.50) | 0.014    | 1.04(0.70,1.56) | 0.024 | 1.04(0.58,1.88) | 0.135 | 1.07(0.52,2.19) | 0.076 | 1.03(0.72,1.47) | 0.058 |
| PCR-RFLR    | 8   | 1.02(0.83,1.25) | <0.001   | 1.11(0.85,1.44) | <0.001 | 0.94(0.67,1.32) | <0.001 | 0.99(0.65,1.51) | <0.001 | 1.12(0.88,1.42) | <0.001 |
| Taqman      | 4   | 1.11(0.87,1.40) | 0.005    | 1.10(0.85,1.42) | 0.024 | 1.25(0.80,1.95) | 0.281 | 1.28(0.76,2.16) | 0.009 | 1.07(0.86,1.34) | 0.116 |
| Other methods | 2   | 1.18(0.86,1.60) | 0.008    | 1.12(0.91,1.37) | 0.124 | 1.39(0.62,3.10) | 0.018 | 1.44(0.61,3.38) | 0.013 | 1.07(0.96,1.18) | 0.333 |

OR, Odds ratio; CI, confidence interval; SOC, source of controls; HB, hospital-based controls; PB, population-based controls; HWE, Hardy-Weinberg equilibrium; PCR-RFLR, polymerase chain reaction-restriction fragment length polymorphism.

Table 4 False-positive report probability values for associations between COX-2 rs689466 polymorphism and colorectal cancer risk.

| Variables | OR (95%CI) | $p$ value | Power | Prior Probability |
|-----------|-----------|-----------|--------|-------------------|
|           | 0.25      | 0.1       | 0.01   | 0.001             | 0.0001 |
| A vs. G   | 1.15(1.02,1.29) | 0.025 | 0.898 | 0.533 | 0.774 | 0.974 | 0.997 | 1.000 |
| Caucasian |           |          |        |                   |       |
| AA+AG vs. GG | 1.14(1.00,1.30) | 0.046 | 0.800 | 0.561 | 0.793 | 0.977 | 0.998 | 1.000 |
| Caucasian | AA vs. GG |           |        |                   |       |
| HB        | 1.33(1.00,1.78) | 0.048 | 0.789 | 0.517 | 0.763 | 0.972 | 0.997 | 1.000 |

OR, Odds ratio; CI, confidence interval; HB, hospital-based controls.

Figures
Figure 1

Selection for eligible papers included in this meta-analysis

Articles identified after databases searching (n=161)

→ 43 articles excluded for duplication

Articles remained after duplicates n=118

→ 75 articles excluded based on titles and abstracts

Full text assessed for eligibility (n=43)

Articles excluded for other diseases (n=10)
- No genotype data (n=2)
- Other SNPs (n=7)
- Reviews (n=2)
- Meta-analyses (n=5)
- Not case-control study (n=1)

Articles included in this meta-analysis (n=16)
Figure 2

The association between COX-2 expression levels and overall survival of CRC.

HR=0.66(0.45-0.98)
Logrank p-value = 0.0357
Figure 3

Forest plot shows odds ratio for the association between COX-2 rs689466 polymorphism and CRC risk (G vs. A)
| Study ID          | OR (95% CI)       | Weight |
|-------------------|-------------------|--------|
| Caucasian         |                   |        |
| Siezen2005        | 1.27 (0.99, 1.62) | 6.23   |
| Siezen2006        | 0.87 (0.73, 1.03) | 7.19   |
| Andersen2009      | 0.98 (0.78, 1.22) | 6.53   |
| Hoff2009          | 0.93 (0.71, 1.21) | 5.95   |
| Thomopson2009     | 0.87 (0.69, 1.10) | 6.37   |
| Pereira2010       | 1.40 (0.95, 2.06) | 4.44   |
| Andersen2013      | 1.13 (0.98, 1.30) | 7.60   |
| Makar2013         | 1.02 (0.93, 1.12) | 8.04   |
| Pereira2014       | 1.46 (1.12, 1.91) | 5.91   |
| Vogel2014         | 1.40 (1.13, 1.73) | 6.65   |
| Shomat2015        | 2.57 (1.60, 4.12) | 3.60   |
| Tomitao2017       | 1.28 (0.91, 1.81) | 4.92   |
| Subtotal (I-squared = 73.0%, p = 0.000) | 1.15 (1.02, 1.29) | 73.45 |
| Asian             |                   |        |
| Tan2007           | 0.76 (0.68, 0.86) | 7.83   |
| Zhang2012         | 0.71 (0.57, 0.87) | 6.65   |
| Ruan2013          | 0.77 (0.54, 1.10) | 4.85   |
| Li2013            | 1.07 (0.90, 1.27) | 7.22   |
| Subtotal (I-squared = 77.1%, p = 0.004) | 0.82 (0.67, 1.01) | 26.55 |
| Overall (I-squared = 81.7%, p = 0.000) | 1.06 (0.94, 1.19) | 100.00 |

NOTE: Weights are from random effects analysis

---

**Figure 4**

Stratification analyses of ethnicity between COX-2 rs689466 polymorphism and CRC risk (G vs. A)
Figure 5

Begg's tests for publication bias between COX-2 rs689466 polymorphism and CRC risk (GG+ AG vs. AA)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFigure1.tif